Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

Eli Lilly (NYSE:LLY) has inked a deal worth up to $1B with HAYA Therapeutics, a biotech focused on a cell information ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this ...

Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

Eli Lilly will work with RNA-focused Haya Therapeutics to search for new targets to develop drugs for metabolic conditions ...